oxonic acid has been researched along with Cholera Infantum in 12 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 9.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 9.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| "Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites." | 5.19 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014) |
| "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer." | 5.17 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. ( Akashi, K; Arita, S; Baba, E; Esaki, T; Kishimoto, J; Kumagai, H; Kusaba, H; Mitsugi, K; Uchino, K, 2013) |
| " The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL." | 2.82 | Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer. ( Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M, 2016) |
| " Pharmacokinetic data are consistent with potent modulation of 5-fluorouracil (5-FU) by CDHP, with prolonged half-life and 5-FU AUC at least 10-fold higher than reported in previous studies of equitoxic doses of tegafur modulated by uracil." | 2.70 | Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. ( Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002) |
| "Treatment with uric acid protected Caco-2 cells from indomethacin-induced oxidative stress, lipid peroxidation, and cytotoxicity." | 1.46 | Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. ( Furuhashi, H; Higashiyama, M; Hokari, R; Komoto, S; Kurihara, C; Maruta, K; Matsuo, H; Miura, S; Nagao, S; Narimatsu, K; Okada, Y; Sato, H; Shirakabe, K; Takajo, T; Tomita, K; Watanabe, C; Yasutake, Y; Yoshikawa, K, 2017) |
| " With regard to adverse events, the rates of nausea (p<0." | 1.42 | [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015) |
| " Gastrointestinal toxicity was evaluated by Common Toxicity Criteria for Adverse Events version 4." | 1.42 | Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs. ( Fujino, Y; Goji, T; Kimura, T; Kitamura, S; Miyamoto, H; Miyoshi, J; Muguruma, N; Okahisa, T; Okamoto, K; Sogabe, M; Takayama, T; Taniguchi, T; Tomonari, T, 2015) |
| " on days 1-28, every 6 weeks) and assessed for all adverse events." | 1.35 | Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2008) |
| " The reduction of gastrointestinal (GI) toxicity, induced in the host by 5-FU, was modulated by potassium oxonate (Oxo), an inhibitor of orotate phosphoribosyltransferase that catalyzes the phosphorylation of 5-FU, a process believed to be responsible for the toxic effects of 5-FU." | 1.29 | Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. ( Fukushima, M; Kato, T; Ohshimo, H; Shimamato, Y; Shirasaka, T; Yamaguchi, M; Yonekura, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahara, N | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Sasaki, T | 1 |
| Ishigami, H | 1 |
| Yamashita, H | 1 |
| Yamaguchi, H | 1 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Mizuno, S | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Yamamoto, N | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Ijichi, H | 1 |
| Tateishi, K | 1 |
| Tada, M | 1 |
| Kitayama, J | 1 |
| Watanabe, T | 1 |
| Koike, K | 1 |
| Kajiwara, T | 1 |
| Miura, K | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Komura, T | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shirasaka, T | 2 |
| Unno, M | 1 |
| Tanaka, H | 1 |
| Mitsunaga, S | 1 |
| Kobayashi, M | 1 |
| Funazaki, H | 1 |
| Katayama, S | 1 |
| Kuwahara, A | 1 |
| Okuyama, H | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Sakamoto, Y | 1 |
| Kondo, S | 1 |
| Morizane, C | 1 |
| Ueno, H | 1 |
| Okusaka, T | 1 |
| Ochiai, A | 1 |
| Ikeda, M | 1 |
| Miyoshi, J | 1 |
| Miyamoto, H | 1 |
| Goji, T | 1 |
| Taniguchi, T | 1 |
| Tomonari, T | 1 |
| Sogabe, M | 1 |
| Kimura, T | 1 |
| Kitamura, S | 1 |
| Okamoto, K | 1 |
| Fujino, Y | 1 |
| Muguruma, N | 1 |
| Okahisa, T | 1 |
| Takayama, T | 1 |
| Aotani, E | 1 |
| Hamano, T | 1 |
| Gemma, A | 1 |
| Takeuchi, M | 1 |
| Takebayashi, T | 1 |
| Kobayashi, K | 1 |
| Yasutake, Y | 1 |
| Tomita, K | 1 |
| Higashiyama, M | 1 |
| Furuhashi, H | 1 |
| Shirakabe, K | 1 |
| Takajo, T | 1 |
| Maruta, K | 1 |
| Sato, H | 1 |
| Narimatsu, K | 1 |
| Yoshikawa, K | 1 |
| Okada, Y | 1 |
| Kurihara, C | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Nagao, S | 1 |
| Matsuo, H | 1 |
| Miura, S | 1 |
| Hokari, R | 1 |
| Choi, IS | 1 |
| Lee, KW | 1 |
| Kim, KH | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Lee, JS | 1 |
| Kusaba, H | 1 |
| Esaki, T | 1 |
| Kishimoto, J | 1 |
| Uchino, K | 1 |
| Arita, S | 1 |
| Kumagai, H | 1 |
| Mitsugi, K | 1 |
| Akashi, K | 1 |
| Baba, E | 1 |
| Cohen, SJ | 1 |
| Leichman, CG | 1 |
| Yeslow, G | 1 |
| Beard, M | 1 |
| Proefrock, A | 1 |
| Roedig, B | 1 |
| Damle, B | 1 |
| Letrent, SP | 1 |
| DeCillis, AP | 1 |
| Meropol, NJ | 1 |
| Yamanaka, T | 1 |
| Matsumoto, S | 1 |
| Teramukai, S | 1 |
| Ishiwata, R | 1 |
| Nagai, Y | 1 |
| Fukushima, M | 2 |
| Nakajo, A | 1 |
| Hokita, S | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Etoh, T | 1 |
| Hamanoue, M | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Aridome, K | 1 |
| Morita, S | 1 |
| Natsugoe, S | 1 |
| Takiuchi, H | 1 |
| Nakano, S | 1 |
| Maehara, Y | 1 |
| Sakamoto, J | 1 |
| Aikou, T | 1 |
| Shimamato, Y | 1 |
| Ohshimo, H | 1 |
| Yamaguchi, M | 1 |
| Kato, T | 1 |
| Yonekura, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for oxonic acid and Cholera Infantum
| Article | Year |
|---|---|
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin | 2016 |
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2010 |
Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2002 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
6 other studies available for oxonic acid and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; G | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointest | 2015 |
Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Disease Models | 2017 |
Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cohort Studies; Drug Combin | 2008 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Drug Sy | 1996 |